You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of a novel highly effective influenza vaccine
SBC: FLUGEN INC Topic: NIAIDDESCRIPTION provided by applicant Seasonal influenza flu virus an NIAID category C priority pathogen causes widespread infection resulting in at least million cases of severe illness and deaths worldwide Young children and elderly or immunocompromised individuals are typically at greater risk of severe illness or death from influenza Newly emerging strains can result ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
New heterocyclic inhibitors of filoviruses
SBC: MICROBIOTIX, INC. Topic: HDESCRIPTION provided by applicant Ebola and Marburg viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral i ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Nitric Oxide Microfluidic Sensor
SBC: CLINICAL SENSORS, INC. Topic: NIAIDDESCRIPTION provided by applicant This Small Business Innovation Research SBIR Phase I project aims to develop a microfluidic based nitric oxide NO sensor as an early sepsis risk assessment device Sepsis causes significant strain on the U S healthcare system consuming over $ billion annually due to extended hospital stays and significant morbidity and mortality Rapid diagnosis and in ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
New small molecule inhibitors of arenaviruses
SBC: MICROBIOTIX, INC. Topic: RDESCRIPTION provided by applicant Lassa fever virus LASV and Machupo virus MACV are hemorrhagic fever arenaviruses which are classified as Category A Agents Currently there are no licensed LASV or MACV vaccines and LASV MACV therapy is limited to use of the nucleoside analog ribavirin which is only partially effective and associated with significant side effects The impact of arenavirus ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Live-attenuated ETEC Anti-Diarrhea Vaccine Construction via Synthetic Biology
SBC: Codagenix Inc. Topic: NIAIDDESCRIPTION provided by applicant The development of vaccine to combat Enterotoxigenic E coli ETEC is vital given the pathogenandapos s global impact on million individuals annually however an entirely new non conventional approach is needed Field studies have suggested that inert antigen based vaccines to combat ETEC have andquot essentially no efficacyandquot Therefore a vaccin ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of an Antigen Capture Assay for Babesia microti
SBC: BIOPEPTIDES CORP Topic: NIAIDDESCRIPTION provided by applicant Babesia microti the primary etiologic agent of human babesiosis is a tick borne eukaryotic apicomplexan pathogen that is an increasing threat to the US public health Although B microti is primarily a tick borne pathogen it can be transmitted by transfusion of infected blood Despite the well recognized threat there is no FDA licensed test to screen donor ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Novel commensal polysaccharide treats multiple sclerosis through Treg modulation
SBC: SYMBIOTIX BIOTHERAPIES, INC. Topic: NIAIDAbstract Multiple sclerosis (MS) is a chronic demyelinating inflammatory disease that is the most common neurological disease of young adults, affecting over 350,000 patients in the US and over 2.5 million patients worldwide. MS is a disease of high unmetmedical need, currently treatable with one of several approved drugs, all of which result in either immune modulation or significant immunosuppre ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
TLR5 Antagonists for Infectious Disease Therapy
SBC: MICROBIOTIX, INC. Topic: N/ADESCRIPTION (provided by applicant): A family of conserved toll-like receptors (TLRs) found on a variety of human cell types plays an important role in recognition of invading pathogens and in mounting an effective inflammatory immune response. Each these receptors binds a specific microbial ligand and triggers a signal transduction pathway leading to transcription of genes encoding pro-inflammato ...
STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health -
Stable cationic bacteriochlorins for antimicrobial photodynamic therapy
SBC: NIRVANA PHARMACEUTICALS, INC. Topic: N/ADESCRIPTION (provided by applicant): This proposal describes a breakthrough development involving the chemical design and synthesis of stabilized bacteriochlorin molecules to carry out photodynamic therapy. These novel photosensitizers (PS) have very intense absorption bands in the near-infrared region of the spectrum where tissue penetration is maximized and good yields of the triplet excited sta ...
STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health -
Nicotinic Ligands as Smoking Cessation Agents
SBC: PGI HOLDING CORPORATION Topic: N/ADESCRIPTION (provided by applicant): Tobacco use and nicotine addiction are an immense burden on the public health. There are an estimated 44.5 million (21%) adult smokers and an estimated 3.75 million (22%) high school student smokers in the US. Tobacco use is responsible for over 440,000 deaths per year in the US, which accounts for 1 in every 5 total deaths. Approximately 70% of the adult smoke ...
STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health